News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Sep 14, 2020
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of...
-
Aug 6, 2020
- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC, Aug. 6, 2020 /CNW/ - Sierra Oncology, Inc....
-
Aug 6, 2020
- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of momelotinib to ruxolitinib from the SIMPLIFY-1...
-
Jul 28, 2020
- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company - VANCOUVER, British Columbia,...
-
Jun 12, 2020
- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib - -...
-
May 27, 2020
- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28th – - Jefferies Global Virtual Healthcare Conference at 4:30 p.m. ET on June 3rd - VANCOUVER, May 27, 2020 /CNW/...
-
May 26, 2020
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...
-
May 14, 2020
- Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity - - Long-term safety profile reinforces lack of...
-
May 7, 2020
- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th - VANCOUVER, May 7, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug...
-
May 7, 2020
- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines - - Publications...